
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
The treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:0
Koselugo is suitable for treating children aged 2 years and above with type 1 neurofibromatosis.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:4
Alpelisib combined with Fluvastatin in the treatment of postmenopausal women and men with breast cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:4
Balversa is suitable for treating adult patients with locally advanced or metastatic urothelial carcinoma.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:5
Stiripentol is suitable for treating epileptic seizures associated with Dravet syndrome (DS).【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:12
Used for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults and children aged 6 months and older.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:3
Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:15
Lenvatinib is indicated for differentiated thyroid carcinoma (DTC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and endometrial carcinoma (EC).【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:0
Tucatinib can be used to treat breast cancer and colorectal cancer in adult patients.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:0
Vigabatrin is an adjuvant therapy for refractory complex partial epilepsy patients aged 2 years and above.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:0
Entrectinib is a Broad-spectrum antitumor agents.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:7
Upadacitinib can regulate abnormal immune responses, alleviate inflammation and symptoms of diseases.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:6
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:932025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: